#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Recent Progress of Antiprotozoan Agents
1-1	0-2	2.	_	_	_	_
1-2	3-9	Recent	abstract[1]	new[1]	_	_
1-3	10-18	Progress	abstract[1]	new[1]	_	_
1-4	19-21	of	abstract[1]	new[1]	_	_
1-5	22-35	Antiprotozoan	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-6	36-42	Agents	abstract[1]|abstract[2]	new[1]|new[2]	_	_

#Text=2.1. Anti-Giardiasis
2-1	43-47	2.1.	_	_	_	_
2-2	48-63	Anti-Giardiasis	person	new	_	_

#Text=Giardiasis is caused by the protozoan parasite G. intestinalis ( also known as G. lamblia or G. duodenalis ) .
3-1	64-74	Giardiasis	abstract	new	ana	4-1
3-2	75-77	is	_	_	_	_
3-3	78-84	caused	_	_	_	_
3-4	85-87	by	_	_	_	_
3-5	88-91	the	person[6]|person[7]	new[6]|giv[7]	coref|coref	3-5[7_6]|3-14[8_7]
3-6	92-101	protozoan	abstract|person[6]|person[7]	new|new[6]|giv[7]	coref	7-16[34_0]
3-7	102-110	parasite	person[6]|person[7]	new[6]|giv[7]	_	_
3-8	111-113	G.	person[6]|person[7]	new[6]|giv[7]	_	_
3-9	114-126	intestinalis	person[6]|person[7]	new[6]|giv[7]	_	_
3-10	127-128	(	person[6]|person[7]	new[6]|giv[7]	_	_
3-11	129-133	also	person[6]|person[7]	new[6]|giv[7]	_	_
3-12	134-139	known	person[6]|person[7]	new[6]|giv[7]	_	_
3-13	140-142	as	person[6]|person[7]	new[6]|giv[7]	_	_
3-14	143-145	G.	person[6]|person[7]|person[8]	new[6]|giv[7]|giv[8]	coref	3-17[9_8]
3-15	146-153	lamblia	person[6]|person[7]|person[8]	new[6]|giv[7]|giv[8]	_	_
3-16	154-156	or	person[6]|person[7]	new[6]|giv[7]	_	_
3-17	157-159	G.	person[6]|person[7]|person[9]	new[6]|giv[7]|giv[9]	coref	26-3[161_9]
3-18	160-170	duodenalis	person[6]|person[7]|person[9]	new[6]|giv[7]|giv[9]	_	_
3-19	171-172	)	person[6]|person[7]	new[6]|giv[7]	_	_
3-20	173-174	.	_	_	_	_

#Text=It is also known by the common name “ beaver fever , ” because this infection was reported in campers who drank contaminated water that was inhabited by beavers .
4-1	175-177	It	abstract	giv	coref	4-15[14_0]
4-2	178-180	is	_	_	_	_
4-3	181-185	also	_	_	_	_
4-4	186-191	known	_	_	_	_
4-5	192-194	by	_	_	_	_
4-6	195-198	the	abstract[11]	new[11]	appos	4-10[13_11]
4-7	199-205	common	abstract[11]	new[11]	_	_
4-8	206-210	name	abstract[11]	new[11]	_	_
4-9	211-212	“	_	_	_	_
4-10	213-219	beaver	animal|abstract[13]	new|giv[13]	_	_
4-11	220-225	fever	abstract[13]	giv[13]	_	_
4-12	226-227	,	_	_	_	_
4-13	228-229	”	_	_	_	_
4-14	230-237	because	_	_	_	_
4-15	238-242	this	abstract[14]	giv[14]	coref	5-1[0_14]
4-16	243-252	infection	abstract[14]	giv[14]	_	_
4-17	253-256	was	_	_	_	_
4-18	257-265	reported	_	_	_	_
4-19	266-268	in	_	_	_	_
4-20	269-276	campers	place[15]	new[15]	_	_
4-21	277-280	who	place[15]	new[15]	_	_
4-22	281-286	drank	place[15]	new[15]	_	_
4-23	287-299	contaminated	place[15]|substance[16]	new[15]|new[16]	coref	8-13[41_16]
4-24	300-305	water	place[15]|substance[16]	new[15]|new[16]	_	_
4-25	306-310	that	place[15]|substance[16]	new[15]|new[16]	_	_
4-26	311-314	was	place[15]|substance[16]	new[15]|new[16]	_	_
4-27	315-324	inhabited	place[15]|substance[16]	new[15]|new[16]	_	_
4-28	325-327	by	place[15]|substance[16]	new[15]|new[16]	_	_
4-29	328-335	beavers	place[15]|substance[16]|animal	new[15]|new[16]|new	_	_
4-30	336-337	.	_	_	_	_

#Text=Giardiasis is the most common protozoan infection in human beings , and it occurs in both developing and industrialized countries .
5-1	338-348	Giardiasis	abstract	giv	coref	5-3[19_0]
5-2	349-351	is	_	_	_	_
5-3	352-355	the	abstract[19]	giv[19]	ana	5-13[0_19]
5-4	356-360	most	abstract[19]	giv[19]	_	_
5-5	361-367	common	abstract[19]	giv[19]	_	_
5-6	368-377	protozoan	abstract[19]	giv[19]	_	_
5-7	378-387	infection	abstract[19]	giv[19]	_	_
5-8	388-390	in	abstract[19]	giv[19]	_	_
5-9	391-396	human	abstract[19]|animal[20]	giv[19]|new[20]	coref	23-27[141_20]
5-10	397-403	beings	abstract[19]|animal[20]	giv[19]|new[20]	_	_
5-11	404-405	,	_	_	_	_
5-12	406-409	and	_	_	_	_
5-13	410-412	it	abstract	giv	ana	6-1
5-14	413-419	occurs	_	_	_	_
5-15	420-422	in	_	_	_	_
5-16	423-427	both	place[22]	new[22]	coref	8-7[38_22]
5-17	428-438	developing	place[22]	new[22]	_	_
5-18	439-442	and	place[22]	new[22]	_	_
5-19	443-457	industrialized	place[22]	new[22]	_	_
5-20	458-467	countries	place[22]	new[22]	_	_
5-21	468-469	.	_	_	_	_

#Text=Its global incidence is believed to range between 20 % – 60 % , with 2 % – 7 % incidence in industrialized nations .
6-1	470-473	Its	abstract|abstract[24]	giv|new[24]	coref|coref	6-16[28_24]|8-1[37_0]
6-2	474-480	global	abstract[24]	new[24]	_	_
6-3	481-490	incidence	abstract[24]	new[24]	_	_
6-4	491-493	is	_	_	_	_
6-5	494-502	believed	_	_	_	_
6-6	503-505	to	_	_	_	_
6-7	506-511	range	_	_	_	_
6-8	512-519	between	_	_	_	_
6-9	520-522	20	abstract[25]	new[25]	_	_
6-10	523-524	%	abstract[25]	new[25]	_	_
6-11	525-526	–	abstract[25]	new[25]	_	_
6-12	527-529	60	abstract[25]|abstract[26]	new[25]|new[26]	coref	6-20[0_26]
6-13	530-531	%	abstract[25]|abstract[26]	new[25]|new[26]	_	_
6-14	532-533	,	_	_	_	_
6-15	534-538	with	_	_	_	_
6-16	539-540	2	abstract[28]	giv[28]	_	_
6-17	541-542	%	abstract[28]	giv[28]	_	_
6-18	543-544	–	abstract[28]	giv[28]	_	_
6-19	545-546	7	abstract[28]	giv[28]	_	_
6-20	547-548	%	abstract|abstract[28]	giv|giv[28]	_	_
6-21	549-558	incidence	abstract[28]	giv[28]	_	_
6-22	559-561	in	abstract[28]	giv[28]	_	_
6-23	562-576	industrialized	abstract[28]|place[29]	giv[28]|new[29]	_	_
6-24	577-584	nations	abstract[28]|place[29]	giv[28]|new[29]	_	_
6-25	585-586	.	_	_	_	_

#Text=Giardia intestinalis was first described in 1681 after the Dutch microscopist Antonie van Leeuwenhoek observed the protozoan in his own diarrheic stools .
7-1	587-594	Giardia	abstract	new	_	_
7-2	595-607	intestinalis	abstract	new	_	_
7-3	608-611	was	_	_	_	_
7-4	612-617	first	_	_	_	_
7-5	618-627	described	_	_	_	_
7-6	628-630	in	_	_	_	_
7-7	631-635	1681	time	new	_	_
7-8	636-641	after	_	_	_	_
7-9	642-645	the	person[33]	new[33]	ana	7-19[0_33]
7-10	646-651	Dutch	person[33]	new[33]	_	_
7-11	652-664	microscopist	person[33]	new[33]	_	_
7-12	665-672	Antonie	person[33]	new[33]	_	_
7-13	673-676	van	person[33]	new[33]	_	_
7-14	677-688	Leeuwenhoek	person[33]	new[33]	_	_
7-15	689-697	observed	_	_	_	_
7-16	698-701	the	abstract[34]	giv[34]	_	_
7-17	702-711	protozoan	abstract[34]	giv[34]	_	_
7-18	712-714	in	_	_	_	_
7-19	715-718	his	person|object[36]	giv|new[36]	_	_
7-20	719-722	own	object[36]	new[36]	_	_
7-21	723-732	diarrheic	object[36]	new[36]	_	_
7-22	733-739	stools	object[36]	new[36]	_	_
7-23	740-741	.	_	_	_	_

#Text=This disease is often prevalent in poor countries and communities that have untreated water , inadequate sanitation , and poor dietary status .
8-1	742-746	This	abstract[37]	giv[37]	coref	9-1[45_37]
8-2	747-754	disease	abstract[37]	giv[37]	_	_
8-3	755-757	is	_	_	_	_
8-4	758-763	often	_	_	_	_
8-5	764-773	prevalent	_	_	_	_
8-6	774-776	in	_	_	_	_
8-7	777-781	poor	place[38]|place[39]	giv[38]|giv[39]	coref	8-7[39_38]
8-8	782-791	countries	place[38]|place[39]	giv[38]|giv[39]	_	_
8-9	792-795	and	place[39]	giv[39]	_	_
8-10	796-807	communities	place[39]|organization[40]	giv[39]|new[40]	_	_
8-11	808-812	that	place[39]|organization[40]	giv[39]|new[40]	_	_
8-12	813-817	have	place[39]|organization[40]	giv[39]|new[40]	_	_
8-13	818-827	untreated	place[39]|organization[40]|substance[41]	giv[39]|new[40]|giv[41]	coref	9-19[50_41]
8-14	828-833	water	place[39]|organization[40]|substance[41]	giv[39]|new[40]|giv[41]	_	_
8-15	834-835	,	place[39]|organization[40]	giv[39]|new[40]	_	_
8-16	836-846	inadequate	place[39]|organization[40]|abstract[42]	giv[39]|new[40]|new[42]	_	_
8-17	847-857	sanitation	place[39]|organization[40]|abstract[42]	giv[39]|new[40]|new[42]	_	_
8-18	858-859	,	place[39]|organization[40]	giv[39]|new[40]	_	_
8-19	860-863	and	place[39]|organization[40]	giv[39]|new[40]	_	_
8-20	864-868	poor	place[39]|organization[40]|abstract[44]	giv[39]|new[40]|new[44]	_	_
8-21	869-876	dietary	place[39]|organization[40]|abstract|abstract[44]	giv[39]|new[40]|new|new[44]	_	_
8-22	877-883	status	place[39]|organization[40]|abstract[44]	giv[39]|new[40]|new[44]	_	_
8-23	884-885	.	_	_	_	_

#Text=The infection is caused by fecal – oral transmission and initiated by the ingestion of infectious cysts from contaminated water or through person-to-person contact .
9-1	886-889	The	abstract[45]	giv[45]	coref	11-4[60_45]
9-2	890-899	infection	abstract[45]	giv[45]	_	_
9-3	900-902	is	_	_	_	_
9-4	903-909	caused	_	_	_	_
9-5	910-912	by	_	_	_	_
9-6	913-918	fecal	person|event[47]	new|new[47]	_	_
9-7	919-920	–	event[47]	new[47]	_	_
9-8	921-925	oral	event[47]	new[47]	_	_
9-9	926-938	transmission	event[47]	new[47]	_	_
9-10	939-942	and	_	_	_	_
9-11	943-952	initiated	_	_	_	_
9-12	953-955	by	_	_	_	_
9-13	956-959	the	event[48]	new[48]	_	_
9-14	960-969	ingestion	event[48]	new[48]	_	_
9-15	970-972	of	event[48]	new[48]	_	_
9-16	973-983	infectious	event[48]|substance[49]	new[48]|new[49]	_	_
9-17	984-989	cysts	event[48]|substance[49]	new[48]|new[49]	_	_
9-18	990-994	from	event[48]|substance[49]	new[48]|new[49]	_	_
9-19	995-1007	contaminated	event[48]|substance[49]|substance[50]	new[48]|new[49]|giv[50]	_	_
9-20	1008-1013	water	event[48]|substance[49]|substance[50]	new[48]|new[49]|giv[50]	_	_
9-21	1014-1016	or	_	_	_	_
9-22	1017-1024	through	_	_	_	_
9-23	1025-1041	person-to-person	event[51]	new[51]	_	_
9-24	1042-1049	contact	event[51]	new[51]	_	_
9-25	1050-1051	.	_	_	_	_

#Text=After excystation , flagellated trophozoites colonize the upper small intestine , where they attach to the epithelial lining but do not invade the mucosa .
10-1	1052-1057	After	_	_	_	_
10-2	1058-1069	excystation	event	new	_	_
10-3	1070-1071	,	_	_	_	_
10-4	1072-1083	flagellated	animal[53]	new[53]	ana	10-13[0_53]
10-5	1084-1096	trophozoites	animal[53]	new[53]	_	_
10-6	1097-1105	colonize	_	_	_	_
10-7	1106-1109	the	place[54]	new[54]	_	_
10-8	1110-1115	upper	place[54]	new[54]	_	_
10-9	1116-1121	small	place[54]	new[54]	_	_
10-10	1122-1131	intestine	place[54]	new[54]	_	_
10-11	1132-1133	,	place[54]	new[54]	_	_
10-12	1134-1139	where	place[54]	new[54]	_	_
10-13	1140-1144	they	place[54]|animal	new[54]|giv	_	_
10-14	1145-1151	attach	place[54]	new[54]	_	_
10-15	1152-1154	to	place[54]	new[54]	_	_
10-16	1155-1158	the	place[54]|object[56]	new[54]|new[56]	_	_
10-17	1159-1169	epithelial	place[54]|object[56]	new[54]|new[56]	_	_
10-18	1170-1176	lining	place[54]|object[56]	new[54]|new[56]	_	_
10-19	1177-1180	but	place[54]	new[54]	_	_
10-20	1181-1183	do	place[54]	new[54]	_	_
10-21	1184-1187	not	place[54]	new[54]	_	_
10-22	1188-1194	invade	place[54]	new[54]	_	_
10-23	1195-1198	the	place[54]|object[57]	new[54]|new[57]	_	_
10-24	1199-1205	mucosa	place[54]|object[57]	new[54]|new[57]	_	_
10-25	1206-1207	.	_	_	_	_

#Text=The duration of Giardia infection is variable ; however , chronic infection and reinfection commonly occur .
11-1	1208-1211	The	time[58]	new[58]	_	_
11-2	1212-1220	duration	time[58]	new[58]	_	_
11-3	1221-1223	of	time[58]	new[58]	_	_
11-4	1224-1231	Giardia	time[58]|person|abstract[60]	new[58]|new|giv[60]	coref|coref	11-11[61_60]|15-6
11-5	1232-1241	infection	time[58]|abstract[60]	new[58]|giv[60]	_	_
11-6	1242-1244	is	_	_	_	_
11-7	1245-1253	variable	_	_	_	_
11-8	1254-1255	;	_	_	_	_
11-9	1256-1263	however	_	_	_	_
11-10	1264-1265	,	_	_	_	_
11-11	1266-1273	chronic	abstract[61]	giv[61]	coref	12-10[0_61]
11-12	1274-1283	infection	abstract[61]	giv[61]	_	_
11-13	1284-1287	and	_	_	_	_
11-14	1288-1299	reinfection	event	new	_	_
11-15	1300-1308	commonly	_	_	_	_
11-16	1309-1314	occur	_	_	_	_
11-17	1315-1316	.	_	_	_	_

#Text=Approximately 50 % of the symptoms classically associated with giardiasis are asymptomatic including diarrhea , abdominal pain , nausea , vomiting , and anorexia .
12-1	1317-1330	Approximately	abstract[63]	new[63]	_	_
12-2	1331-1333	50	abstract[63]	new[63]	_	_
12-3	1334-1335	%	abstract[63]	new[63]	_	_
12-4	1336-1338	of	abstract[63]	new[63]	_	_
12-5	1339-1342	the	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-6	1343-1351	symptoms	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-7	1352-1363	classically	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-8	1364-1374	associated	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-9	1375-1379	with	abstract[63]|abstract[64]	new[63]|new[64]	_	_
12-10	1380-1390	giardiasis	abstract[63]|abstract[64]|abstract	new[63]|new[64]|giv	coref	15-35[89_0]
12-11	1391-1394	are	_	_	_	_
12-12	1395-1407	asymptomatic	_	_	_	_
12-13	1408-1417	including	_	_	_	_
12-14	1418-1426	diarrhea	abstract	new	coref	23-18
12-15	1427-1428	,	_	_	_	_
12-16	1429-1438	abdominal	abstract[67]	new[67]	coref	23-15[137_67]
12-17	1439-1443	pain	abstract[67]	new[67]	_	_
12-18	1444-1445	,	_	_	_	_
12-19	1446-1452	nausea	abstract	new	coref	23-21
12-20	1453-1454	,	_	_	_	_
12-21	1455-1463	vomiting	event	new	_	_
12-22	1464-1465	,	_	_	_	_
12-23	1466-1469	and	_	_	_	_
12-24	1470-1478	anorexia	event	new	_	_
12-25	1479-1480	.	_	_	_	_

#Text=However , infected individuals can also develop extraintestinal and postinfectious complications .
13-1	1481-1488	However	_	_	_	_
13-2	1489-1490	,	_	_	_	_
13-3	1491-1499	infected	person[71]	new[71]	_	_
13-4	1500-1511	individuals	person[71]	new[71]	_	_
13-5	1512-1515	can	_	_	_	_
13-6	1516-1520	also	_	_	_	_
13-7	1521-1528	develop	event	new	coref|none	27-6[165_0]|13-7[0_165]
13-8	1529-1544	extraintestinal	abstract[72]	new[72]	_	_
13-9	1545-1548	and	abstract[72]	new[72]	_	_
13-10	1549-1563	postinfectious	abstract[72]	new[72]	_	_
13-11	1564-1577	complications	abstract[72]	new[72]	_	_
13-12	1578-1579	.	_	_	_	_

#Text=Chronic extraintestinal sequelae may affect the joints , skin , eyes , and central nervous system , but the underlying mechanisms are unknown .
14-1	1580-1587	Chronic	abstract[73]	new[73]	_	_
14-2	1588-1603	extraintestinal	abstract[73]	new[73]	_	_
14-3	1604-1612	sequelae	abstract[73]	new[73]	_	_
14-4	1613-1616	may	_	_	_	_
14-5	1617-1623	affect	_	_	_	_
14-6	1624-1627	the	object[74]	new[74]	_	_
14-7	1628-1634	joints	object[74]	new[74]	_	_
14-8	1635-1636	,	_	_	_	_
14-9	1637-1641	skin	object	new	_	_
14-10	1642-1643	,	_	_	_	_
14-11	1644-1648	eyes	object	new	_	_
14-12	1649-1650	,	_	_	_	_
14-13	1651-1654	and	_	_	_	_
14-14	1655-1662	central	place[77]	new[77]	_	_
14-15	1663-1670	nervous	place[77]	new[77]	_	_
14-16	1671-1677	system	place[77]	new[77]	_	_
14-17	1678-1679	,	_	_	_	_
14-18	1680-1683	but	_	_	_	_
14-19	1684-1687	the	abstract[78]	new[78]	_	_
14-20	1688-1698	underlying	abstract[78]	new[78]	_	_
14-21	1699-1709	mechanisms	abstract[78]	new[78]	_	_
14-22	1710-1713	are	_	_	_	_
14-23	1714-1721	unknown	_	_	_	_
14-24	1722-1723	.	_	_	_	_

#Text=According to research data , Giardia has eight distinct genetic assemblages labelled as assemblage “ A ” through “ H ” , and assemblages “ A ” and “ B ” are responsible for infection in humans .
15-1	1724-1733	According	_	_	_	_
15-2	1734-1736	to	_	_	_	_
15-3	1737-1745	research	abstract|abstract[80]	new|new[80]	coref	27-3[164_0]
15-4	1746-1750	data	abstract[80]	new[80]	_	_
15-5	1751-1752	,	_	_	_	_
15-6	1753-1760	Giardia	person	giv	coref	20-23
15-7	1761-1764	has	_	_	_	_
15-8	1765-1770	eight	object[82]	new[82]	coref	15-24[0_82]
15-9	1771-1779	distinct	object[82]	new[82]	_	_
15-10	1780-1787	genetic	object[82]	new[82]	_	_
15-11	1788-1799	assemblages	object[82]	new[82]	_	_
15-12	1800-1808	labelled	object[82]	new[82]	_	_
15-13	1809-1811	as	object[82]	new[82]	_	_
15-14	1812-1822	assemblage	object[82]|object	new[82]|new	appos	15-16
15-15	1823-1824	“	_	_	_	_
15-16	1825-1826	A	object	giv	appos	15-26
15-17	1827-1828	”	_	_	_	_
15-18	1829-1836	through	_	_	_	_
15-19	1837-1838	“	_	_	_	_
15-20	1839-1840	H	abstract	new	_	_
15-21	1841-1842	”	_	_	_	_
15-22	1843-1844	,	_	_	_	_
15-23	1845-1848	and	_	_	_	_
15-24	1849-1860	assemblages	object	giv	_	_
15-25	1861-1862	“	_	_	_	_
15-26	1863-1864	A	object	giv	_	_
15-27	1865-1866	”	_	_	_	_
15-28	1867-1870	and	_	_	_	_
15-29	1871-1872	“	_	_	_	_
15-30	1873-1874	B	place	new	_	_
15-31	1875-1876	”	_	_	_	_
15-32	1877-1880	are	_	_	_	_
15-33	1881-1892	responsible	_	_	_	_
15-34	1893-1896	for	_	_	_	_
15-35	1897-1906	infection	abstract[89]	giv[89]	coref	16-12[0_89]
15-36	1907-1909	in	abstract[89]	giv[89]	_	_
15-37	1910-1916	humans	abstract[89]|animal	giv[89]|new	_	_
15-38	1917-1918	.	_	_	_	_

#Text=Three classes of drugs are currently used for the treatment of giardiasis : metronidazole , mepacrine analogs , and nitrofurans , such as furazolidone (
16-1	1919-1924	Three	person[91]	new[91]	_	_
16-2	1925-1932	classes	person[91]	new[91]	_	_
16-3	1933-1935	of	person[91]	new[91]	_	_
16-4	1936-1941	drugs	person[91]|substance	new[91]|new	coref	24-22[147_0]
16-5	1942-1945	are	_	_	_	_
16-6	1946-1955	currently	_	_	_	_
16-7	1956-1960	used	_	_	_	_
16-8	1961-1964	for	_	_	_	_
16-9	1965-1968	the	abstract[93]	new[93]	coref	21-17[128_93]
16-10	1969-1978	treatment	abstract[93]	new[93]	_	_
16-11	1979-1981	of	abstract[93]	new[93]	_	_
16-12	1982-1992	giardiasis	abstract[93]|abstract	new[93]|giv	coref	19-12
16-13	1993-1994	:	_	_	_	_
16-14	1995-2008	metronidazole	_	_	_	_
16-15	2009-2010	,	_	_	_	_
16-16	2011-2020	mepacrine	animal	new	coref	24-1
16-17	2021-2028	analogs	_	_	_	_
16-18	2029-2030	,	_	_	_	_
16-19	2031-2034	and	_	_	_	_
16-20	2035-2046	nitrofurans	_	_	_	_
16-21	2047-2048	,	_	_	_	_
16-22	2049-2053	such	_	_	_	_
16-23	2054-2056	as	_	_	_	_
16-24	2057-2069	furazolidone	substance	new	coref	25-1
16-25	2070-2071	(	_	_	_	_

#Text=Figure 1
17-1	2072-2078	Figure	abstract[97]	new[97]	_	_
17-2	2079-2080	1	abstract[97]	new[97]	_	_

#Text=) .
18-1	2081-2082	)	_	_	_	_
18-2	2083-2084	.	_	_	_	_

#Text=Metronidazole is the most widely used drug for the treatment of giardiasis globally and it is generally effective and well-tolerated .
19-1	2085-2098	Metronidazole	substance	new	coref	19-3[99_0]
19-2	2099-2101	is	_	_	_	_
19-3	2102-2105	the	substance[99]	giv[99]	ana	19-15[0_99]
19-4	2106-2110	most	substance[99]	giv[99]	_	_
19-5	2111-2117	widely	substance[99]	giv[99]	_	_
19-6	2118-2122	used	substance[99]	giv[99]	_	_
19-7	2123-2127	drug	substance[99]	giv[99]	_	_
19-8	2128-2131	for	substance[99]	giv[99]	_	_
19-9	2132-2135	the	substance[99]|event[100]	giv[99]|new[100]	_	_
19-10	2136-2145	treatment	substance[99]|event[100]	giv[99]|new[100]	_	_
19-11	2146-2148	of	substance[99]|event[100]	giv[99]|new[100]	_	_
19-12	2149-2159	giardiasis	substance[99]|event[100]|abstract	giv[99]|new[100]|giv	coref	20-23[110_0]
19-13	2160-2168	globally	substance[99]|event[100]	giv[99]|new[100]	_	_
19-14	2169-2172	and	_	_	_	_
19-15	2173-2175	it	substance	giv	coref	20-17[107_0]
19-16	2176-2178	is	_	_	_	_
19-17	2179-2188	generally	_	_	_	_
19-18	2189-2198	effective	_	_	_	_
19-19	2199-2202	and	_	_	_	_
19-20	2203-2217	well-tolerated	_	_	_	_
19-21	2218-2219	.	_	_	_	_

#Text=However , the United States Food and Drug Administration ( FDA ) has not yet approved this drug for the treatment of Giardia infection because of its toxicity and major side effects , such as seizures , ataxia , peripheral neuropathy , transient myopia , gastric mucosal irritation , sperm damage , and hematuria .
20-1	2220-2227	However	_	_	_	_
20-2	2228-2229	,	_	_	_	_
20-3	2230-2233	the	organization[105]	new[105]	appos	20-11[0_105]
20-4	2234-2240	United	place[103]|organization[105]	new[103]|new[105]	coref	24-7[143_103]
20-5	2241-2247	States	place[103]|organization[105]	new[103]|new[105]	_	_
20-6	2248-2252	Food	object|organization[105]	new|new[105]	_	_
20-7	2253-2256	and	organization[105]	new[105]	_	_
20-8	2257-2261	Drug	organization[105]	new[105]	_	_
20-9	2262-2276	Administration	organization[105]	new[105]	_	_
20-10	2277-2278	(	_	_	_	_
20-11	2279-2282	FDA	organization	giv	coref	21-14[127_0]
20-12	2283-2284	)	_	_	_	_
20-13	2285-2288	has	_	_	_	_
20-14	2289-2292	not	_	_	_	_
20-15	2293-2296	yet	_	_	_	_
20-16	2297-2305	approved	_	_	_	_
20-17	2306-2310	this	substance[107]	giv[107]	ana	20-27[0_107]
20-18	2311-2315	drug	substance[107]	giv[107]	_	_
20-19	2316-2319	for	_	_	_	_
20-20	2320-2323	the	abstract[108]	new[108]	_	_
20-21	2324-2333	treatment	abstract[108]	new[108]	_	_
20-22	2334-2336	of	abstract[108]	new[108]	_	_
20-23	2337-2344	Giardia	abstract[108]|person|abstract[110]	new[108]|giv|giv[110]	coref	21-20[0_110]
20-24	2345-2354	infection	abstract[108]|abstract[110]	new[108]|giv[110]	_	_
20-25	2355-2362	because	_	_	_	_
20-26	2363-2365	of	_	_	_	_
20-27	2366-2369	its	substance|abstract[112]	giv|new[112]	coref	26-7[163_0]
20-28	2370-2378	toxicity	abstract[112]	new[112]	_	_
20-29	2379-2382	and	_	_	_	_
20-30	2383-2388	major	abstract[114]	new[114]	coref	23-10[136_114]
20-31	2389-2393	side	abstract|abstract[114]	new|new[114]	coref	25-5
20-32	2394-2401	effects	abstract[114]	new[114]	_	_
20-33	2402-2403	,	abstract[114]	new[114]	_	_
20-34	2404-2408	such	abstract[114]	new[114]	_	_
20-35	2409-2411	as	abstract[114]	new[114]	_	_
20-36	2412-2420	seizures	abstract[114]|event	new[114]|new	_	_
20-37	2421-2422	,	abstract[114]	new[114]	_	_
20-38	2423-2429	ataxia	abstract[114]|abstract	new[114]|new	_	_
20-39	2430-2431	,	abstract[114]	new[114]	_	_
20-40	2432-2442	peripheral	abstract[114]|abstract[117]	new[114]|new[117]	_	_
20-41	2443-2453	neuropathy	abstract[114]|abstract[117]	new[114]|new[117]	_	_
20-42	2454-2455	,	abstract[114]	new[114]	_	_
20-43	2456-2465	transient	abstract[114]|event[118]	new[114]|new[118]	_	_
20-44	2466-2472	myopia	abstract[114]|event[118]	new[114]|new[118]	_	_
20-45	2473-2474	,	abstract[114]	new[114]	_	_
20-46	2475-2482	gastric	abstract[114]|abstract[119]	new[114]|new[119]	_	_
20-47	2483-2490	mucosal	abstract[114]|abstract[119]	new[114]|new[119]	_	_
20-48	2491-2501	irritation	abstract[114]|abstract[119]	new[114]|new[119]	_	_
20-49	2502-2503	,	abstract[114]	new[114]	_	_
20-50	2504-2509	sperm	abstract[114]|substance|event[121]	new[114]|new|new[121]	_	_
20-51	2510-2516	damage	abstract[114]|event[121]	new[114]|new[121]	_	_
20-52	2517-2518	,	abstract[114]	new[114]	_	_
20-53	2519-2522	and	abstract[114]	new[114]	_	_
20-54	2523-2532	hematuria	abstract[114]|abstract	new[114]|new	_	_
20-55	2533-2534	.	_	_	_	_

#Text=Tinidazole is an N1-position modified 5-nitro imidazole , which has been approved by the FDA for the treatment of giardiasis .
21-1	2535-2545	Tinidazole	substance	new	coref	21-3[126_0]
21-2	2546-2548	is	_	_	_	_
21-3	2549-2551	an	substance[126]	giv[126]	_	_
21-4	2552-2563	N1-position	substance|substance[126]	new|giv[126]	_	_
21-5	2564-2572	modified	substance[126]	giv[126]	_	_
21-6	2573-2580	5-nitro	organization|substance[126]	new|giv[126]	_	_
21-7	2581-2590	imidazole	substance[126]	giv[126]	_	_
21-8	2591-2592	,	substance[126]	giv[126]	_	_
21-9	2593-2598	which	substance[126]	giv[126]	_	_
21-10	2599-2602	has	substance[126]	giv[126]	_	_
21-11	2603-2607	been	substance[126]	giv[126]	_	_
21-12	2608-2616	approved	substance[126]	giv[126]	_	_
21-13	2617-2619	by	substance[126]	giv[126]	_	_
21-14	2620-2623	the	substance[126]|organization[127]	giv[126]|giv[127]	_	_
21-15	2624-2627	FDA	substance[126]|organization[127]	giv[126]|giv[127]	_	_
21-16	2628-2631	for	substance[126]	giv[126]	_	_
21-17	2632-2635	the	substance[126]|abstract[128]	giv[126]|giv[128]	coref	27-14[167_128]
21-18	2636-2645	treatment	substance[126]|abstract[128]	giv[126]|giv[128]	_	_
21-19	2646-2648	of	substance[126]|abstract[128]	giv[126]|giv[128]	_	_
21-20	2649-2659	giardiasis	substance[126]|abstract[128]|abstract	giv[126]|giv[128]|giv	coref	27-17
21-21	2660-2661	.	_	_	_	_

#Text=Nitazoxanide ( NTZ ) belongs to an emerging class of 5-nitrothiazole compounds with potential antigiardial activity .
22-1	2662-2674	Nitazoxanide	substance	new	_	_
22-2	2675-2676	(	_	_	_	_
22-3	2677-2680	NTZ	abstract	new	coref	23-4
22-4	2681-2682	)	_	_	_	_
22-5	2683-2690	belongs	_	_	_	_
22-6	2691-2693	to	_	_	_	_
22-7	2694-2696	an	abstract[132]	new[132]	_	_
22-8	2697-2705	emerging	abstract[132]	new[132]	_	_
22-9	2706-2711	class	abstract[132]	new[132]	_	_
22-10	2712-2714	of	abstract[132]	new[132]	_	_
22-11	2715-2730	5-nitrothiazole	abstract[132]|substance[133]	new[132]|new[133]	_	_
22-12	2731-2740	compounds	abstract[132]|substance[133]	new[132]|new[133]	_	_
22-13	2741-2745	with	abstract[132]|substance[133]	new[132]|new[133]	_	_
22-14	2746-2755	potential	abstract[132]|substance[133]|abstract[134]	new[132]|new[133]|new[134]	_	_
22-15	2756-2768	antigiardial	abstract[132]|substance[133]|abstract[134]	new[132]|new[133]|new[134]	_	_
22-16	2769-2777	activity	abstract[132]|substance[133]|abstract[134]	new[132]|new[133]|new[134]	_	_
22-17	2778-2779	.	_	_	_	_

#Text=However , although NTZ is generally well tolerated , some adverse effects such as abdominal pain , diarrhea , and nausea limit the safe use for human beings .
23-1	2780-2787	However	_	_	_	_
23-2	2788-2789	,	_	_	_	_
23-3	2790-2798	although	_	_	_	_
23-4	2799-2802	NTZ	abstract	giv	_	_
23-5	2803-2805	is	_	_	_	_
23-6	2806-2815	generally	_	_	_	_
23-7	2816-2820	well	_	_	_	_
23-8	2821-2830	tolerated	_	_	_	_
23-9	2831-2832	,	_	_	_	_
23-10	2833-2837	some	abstract[136]	giv[136]	coref	25-4[150_136]
23-11	2838-2845	adverse	abstract[136]	giv[136]	_	_
23-12	2846-2853	effects	abstract[136]	giv[136]	_	_
23-13	2854-2858	such	abstract[136]	giv[136]	_	_
23-14	2859-2861	as	abstract[136]	giv[136]	_	_
23-15	2862-2871	abdominal	abstract[136]|abstract[137]	giv[136]|giv[137]	_	_
23-16	2872-2876	pain	abstract[136]|abstract[137]	giv[136]|giv[137]	_	_
23-17	2877-2878	,	abstract[136]	giv[136]	_	_
23-18	2879-2887	diarrhea	abstract[136]|abstract	giv[136]|giv	_	_
23-19	2888-2889	,	abstract[136]	giv[136]	_	_
23-20	2890-2893	and	abstract[136]	giv[136]	_	_
23-21	2894-2900	nausea	abstract[136]|abstract	giv[136]|giv	_	_
23-22	2901-2906	limit	_	_	_	_
23-23	2907-2910	the	event[140]	new[140]	ana	24-12[0_140]
23-24	2911-2915	safe	event[140]	new[140]	_	_
23-25	2916-2919	use	event[140]	new[140]	_	_
23-26	2920-2923	for	event[140]	new[140]	_	_
23-27	2924-2929	human	event[140]|animal[141]	new[140]|giv[141]	_	_
23-28	2930-2936	beings	event[140]|animal[141]	new[140]|giv[141]	_	_
23-29	2937-2938	.	_	_	_	_

#Text=Mepacrine is no longer available in the United States , and it is being replaced in most of its applications with safer and more specific drugs .
24-1	2939-2948	Mepacrine	animal	giv	_	_
24-2	2949-2951	is	_	_	_	_
24-3	2952-2954	no	_	_	_	_
24-4	2955-2961	longer	_	_	_	_
24-5	2962-2971	available	_	_	_	_
24-6	2972-2974	in	_	_	_	_
24-7	2975-2978	the	place[143]	giv[143]	_	_
24-8	2979-2985	United	place[143]	giv[143]	_	_
24-9	2986-2992	States	place[143]	giv[143]	_	_
24-10	2993-2994	,	_	_	_	_
24-11	2995-2998	and	_	_	_	_
24-12	2999-3001	it	event	giv	ana	24-19
24-13	3002-3004	is	_	_	_	_
24-14	3005-3010	being	_	_	_	_
24-15	3011-3019	replaced	_	_	_	_
24-16	3020-3022	in	_	_	_	_
24-17	3023-3027	most	abstract[146]	new[146]	_	_
24-18	3028-3030	of	abstract[146]	new[146]	_	_
24-19	3031-3034	its	event|abstract[146]	giv|new[146]	_	_
24-20	3035-3047	applications	abstract[146]	new[146]	_	_
24-21	3048-3052	with	_	_	_	_
24-22	3053-3058	safer	substance[147]	giv[147]	coref	27-9[166_147]
24-23	3059-3062	and	substance[147]	giv[147]	_	_
24-24	3063-3067	more	substance[147]	giv[147]	_	_
24-25	3068-3076	specific	substance[147]	giv[147]	_	_
24-26	3077-3082	drugs	substance[147]	giv[147]	_	_
24-27	3083-3084	.	_	_	_	_

#Text=Furazolidone also has serious side effects , such as gastrointestinal disturbances , hemolytic anemia , disulfiram-like reactions to alcohol , and hypersensitivity reactions , as well as evidence of tumorigenicity in rodent studies .
25-1	3085-3097	Furazolidone	substance	giv	_	_
25-2	3098-3102	also	_	_	_	_
25-3	3103-3106	has	_	_	_	_
25-4	3107-3114	serious	abstract[150]	giv[150]	_	_
25-5	3115-3119	side	abstract|abstract[150]	giv|giv[150]	_	_
25-6	3120-3127	effects	abstract[150]	giv[150]	_	_
25-7	3128-3129	,	abstract[150]	giv[150]	_	_
25-8	3130-3134	such	abstract[150]	giv[150]	_	_
25-9	3135-3137	as	abstract[150]	giv[150]	_	_
25-10	3138-3154	gastrointestinal	abstract[150]|event[151]	giv[150]|new[151]	_	_
25-11	3155-3167	disturbances	abstract[150]|event[151]	giv[150]|new[151]	_	_
25-12	3168-3169	,	abstract[150]	giv[150]	_	_
25-13	3170-3179	hemolytic	abstract[150]|abstract[152]	giv[150]|new[152]	_	_
25-14	3180-3186	anemia	abstract[150]|abstract[152]	giv[150]|new[152]	_	_
25-15	3187-3188	,	abstract[150]	giv[150]	_	_
25-16	3189-3204	disulfiram-like	abstract[150]|event[153]	giv[150]|new[153]	_	_
25-17	3205-3214	reactions	abstract[150]|event[153]	giv[150]|new[153]	_	_
25-18	3215-3217	to	abstract[150]|event[153]	giv[150]|new[153]	_	_
25-19	3218-3225	alcohol	abstract[150]|event[153]|substance	giv[150]|new[153]|new	_	_
25-20	3226-3227	,	abstract[150]	giv[150]	_	_
25-21	3228-3231	and	abstract[150]	giv[150]	_	_
25-22	3232-3248	hypersensitivity	abstract[150]|event|event[156]	giv[150]|new|new[156]	_	_
25-23	3249-3258	reactions	abstract[150]|event[156]	giv[150]|new[156]	_	_
25-24	3259-3260	,	abstract[150]	giv[150]	_	_
25-25	3261-3263	as	abstract[150]	giv[150]	_	_
25-26	3264-3268	well	abstract[150]	giv[150]	_	_
25-27	3269-3271	as	abstract[150]	giv[150]	_	_
25-28	3272-3280	evidence	abstract[150]|abstract[157]	giv[150]|new[157]	_	_
25-29	3281-3283	of	abstract[150]|abstract[157]	giv[150]|new[157]	_	_
25-30	3284-3298	tumorigenicity	abstract[150]|abstract[157]|abstract	giv[150]|new[157]|new	_	_
25-31	3299-3301	in	abstract[150]|abstract[157]	giv[150]|new[157]	_	_
25-32	3302-3308	rodent	abstract[150]|abstract[157]|animal|abstract[160]	giv[150]|new[157]|new|new[160]	_	_
25-33	3309-3316	studies	abstract[150]|abstract[157]|abstract[160]	giv[150]|new[157]|new[160]	_	_
25-34	3317-3318	.	_	_	_	_

#Text=Furthermore , G. lamblia resistance to this drug has also been reported .
26-1	3319-3330	Furthermore	_	_	_	_
26-2	3331-3332	,	_	_	_	_
26-3	3333-3335	G.	person[161]|abstract[162]	giv[161]|new[162]	_	_
26-4	3336-3343	lamblia	person[161]|abstract[162]	giv[161]|new[162]	_	_
26-5	3344-3354	resistance	abstract[162]	new[162]	_	_
26-6	3355-3357	to	abstract[162]	new[162]	_	_
26-7	3358-3362	this	abstract[162]|substance[163]	new[162]|giv[163]	_	_
26-8	3363-3367	drug	abstract[162]|substance[163]	new[162]|giv[163]	_	_
26-9	3368-3371	has	_	_	_	_
26-10	3372-3376	also	_	_	_	_
26-11	3377-3381	been	_	_	_	_
26-12	3382-3390	reported	_	_	_	_
26-13	3391-3392	.	_	_	_	_

#Text=Therefore , research focusing on the development of novel , alternative drugs for the treatment of giardiasis is highly desirable .
27-1	3393-3402	Therefore	_	_	_	_
27-2	3403-3404	,	_	_	_	_
27-3	3405-3413	research	abstract[164]	giv[164]	_	_
27-4	3414-3422	focusing	abstract[164]	giv[164]	_	_
27-5	3423-3425	on	abstract[164]	giv[164]	_	_
27-6	3426-3429	the	abstract[164]|event[165]	giv[164]|new[165]	_	_
27-7	3430-3441	development	abstract[164]|event[165]	giv[164]|new[165]	_	_
27-8	3442-3444	of	abstract[164]|event[165]	giv[164]|new[165]	_	_
27-9	3445-3450	novel	abstract[164]|event[165]|substance[166]	giv[164]|new[165]|giv[166]	_	_
27-10	3451-3452	,	abstract[164]|event[165]|substance[166]	giv[164]|new[165]|giv[166]	_	_
27-11	3453-3464	alternative	abstract[164]|event[165]|substance[166]	giv[164]|new[165]|giv[166]	_	_
27-12	3465-3470	drugs	abstract[164]|event[165]|substance[166]	giv[164]|new[165]|giv[166]	_	_
27-13	3471-3474	for	abstract[164]|event[165]|substance[166]	giv[164]|new[165]|giv[166]	_	_
27-14	3475-3478	the	abstract[164]|event[165]|substance[166]|abstract[167]	giv[164]|new[165]|giv[166]|giv[167]	coref	28-16[172_167]
27-15	3479-3488	treatment	abstract[164]|event[165]|substance[166]|abstract[167]	giv[164]|new[165]|giv[166]|giv[167]	_	_
27-16	3489-3491	of	abstract[164]|event[165]|substance[166]|abstract[167]	giv[164]|new[165]|giv[166]|giv[167]	_	_
27-17	3492-3502	giardiasis	abstract[164]|event[165]|substance[166]|abstract[167]|abstract	giv[164]|new[165]|giv[166]|giv[167]|giv	coref	28-19
27-18	3503-3505	is	_	_	_	_
27-19	3506-3512	highly	_	_	_	_
27-20	3513-3522	desirable	_	_	_	_
27-21	3523-3524	.	_	_	_	_

#Text=In view of these considerations , researchers have designed and synthesized some novel molecules for the treatment of giardiasis , their results are summarized in Table 1 .
28-1	3525-3527	In	_	_	_	_
28-2	3528-3532	view	_	_	_	_
28-3	3533-3535	of	_	_	_	_
28-4	3536-3541	these	abstract[169]	new[169]	_	_
28-5	3542-3556	considerations	abstract[169]	new[169]	_	_
28-6	3557-3558	,	_	_	_	_
28-7	3559-3570	researchers	person	new	ana	28-21
28-8	3571-3575	have	_	_	_	_
28-9	3576-3584	designed	_	_	_	_
28-10	3585-3588	and	_	_	_	_
28-11	3589-3600	synthesized	_	_	_	_
28-12	3601-3605	some	substance[171]	new[171]	_	_
28-13	3606-3611	novel	substance[171]	new[171]	_	_
28-14	3612-3621	molecules	substance[171]	new[171]	_	_
28-15	3622-3625	for	_	_	_	_
28-16	3626-3629	the	abstract[172]	giv[172]	_	_
28-17	3630-3639	treatment	abstract[172]	giv[172]	_	_
28-18	3640-3642	of	abstract[172]	giv[172]	_	_
28-19	3643-3653	giardiasis	abstract[172]|abstract	giv[172]|giv	_	_
28-20	3654-3655	,	_	_	_	_
28-21	3656-3661	their	person|abstract[175]	giv|new[175]	_	_
28-22	3662-3669	results	abstract[175]	new[175]	_	_
28-23	3670-3673	are	_	_	_	_
28-24	3674-3684	summarized	_	_	_	_
28-25	3685-3687	in	_	_	_	_
28-26	3688-3693	Table	abstract[176]	new[176]	_	_
28-27	3694-3695	1	abstract[176]	new[176]	_	_
28-28	3696-3697	.	_	_	_	_
